GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » Shares Outstanding (EOP)

ProtoKinetix (ProtoKinetix) Shares Outstanding (EOP) : 346.21 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ProtoKinetix's shares outstanding for the quarter that ended in Dec. 2023 was 346.21 Mil.

ProtoKinetix's quarterly shares outstanding increased from Sep. 2023 (338.88 Mil) to Dec. 2023 (346.21 Mil). It means ProtoKinetix issued new shares from Sep. 2023 to Dec. 2023 .

ProtoKinetix's annual shares outstanding increased from Dec. 2022 (322.88 Mil) to Dec. 2023 (346.21 Mil). It means ProtoKinetix issued new shares from Dec. 2022 to Dec. 2023 .


ProtoKinetix Shares Outstanding (EOP) Historical Data

The historical data trend for ProtoKinetix's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix Shares Outstanding (EOP) Chart

ProtoKinetix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 275.40 285.96 297.39 322.88 346.21

ProtoKinetix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 322.88 326.88 335.63 338.88 346.21

Competitive Comparison of ProtoKinetix's Shares Outstanding (EOP)

For the Biotechnology subindustry, ProtoKinetix's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProtoKinetix's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProtoKinetix's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where ProtoKinetix's Shares Outstanding (EOP) falls into.



ProtoKinetix Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


ProtoKinetix  (OTCPK:PKTX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


ProtoKinetix Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


ProtoKinetix (ProtoKinetix) Business Description

Traded in Other Exchanges
N/A
Address
412 Mulberry Street, Marietta, OH, USA, 45750
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Executives
Clarence Edward Smith director, 10 percent owner, officer: President & CEO 1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta officer: CFO 412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young 10 percent owner 6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough director 1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward officer: CFO 705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen director 4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory director 2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior director, officer: CEO PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum director, officer: President C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix (ProtoKinetix) Headlines